Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
IPO Year: 2006
Exchange: NYSE
Website: emergentbiosolutions.com
Recent Analyst Ratings for Emergent BioSolutions Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/30/2024 | $15.00 | Buy | H.C. Wainwright |
| 8/22/2024 | $16.00 | Buy | Rodman & Renshaw |
| 3/7/2024 | $5.00 | Hold → Buy | The Benchmark Company |
| 11/20/2023 | Underweight | JP Morgan | |
| 8/29/2023 | Buy → Hold | The Benchmark Company | |
| 4/10/2023 | $22.00 | Hold → Buy | The Benchmark Company |
| 3/17/2023 | $23.00 → $9.00 | Neutral → Underweight | JP Morgan |
| 11/10/2022 | Buy → Hold | The Benchmark Company | |
| 4/29/2022 | Overweight → Neutral | Cantor Fitzgerald | |
| 3/10/2022 | $37.00 → $40.00 | Equal-Weight | Wells Fargo |
Emergent BioSolutions Inc. Press Releases
Fastest customizable press release news feed in the world
Emergent BioSolutions Announces Stock Repurchase Program
GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company's common stock on or before March 27, 2026. "As Emergent continues the turnaround phase of our multi-year transformation plan, we expect our investment priorities to remain focused on driving long-term growth and profitability," said Joe Papa, president and CEO of Emergent. "This announcement reflects our confidence in the company's strategy, future outlook and cash generation and provides another avenue for us to create long-term value for shareholders, while delivering on our mission to p
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan"). The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the "Equity Award") as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15,
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult patients. KLOXXADO® delivers 8 mg of naloxone hydrochloride per spray in a ready to use nasal spray to reverse the effects of opioid overdose. "The approval of KLOXXADO® Nasal Spray will provide Canadian patients, friends and family members – as well as the healthcare and first responder communities – with an impo
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International. Emergent received approximately $36.5 million at closing, which is subject to customary post-closing adjustments. Pursuant to the sale, Syngene acquired the assets and equipment associated with the Baltimore-Bayview facility. In addition, Emergent retains the rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene. "This deal enables us to streamline operations, while mai
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has recently secured approximately $27 million in international orders targeted for delivery in 2025 associated with its medical countermeasures (MCM) portfolio. These orders will help address potential threats of smallpox and anthrax and will contribute to the overall supply of MCM's to the international market in 2025. "Emergent is a trusted partner to supply communities around the world with medical countermeasures that protect against serious health threats like smallpox and anthrax," said Joe Papa, president and CEO of Emergent. "We are pleased to engage and support global
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and provide trainings on how to administer the life-saving medicineLeading mental health and addiction treatment services provider, Pathway Healthcare, breaks down stigma and access barriers by making NARCAN® Nasal Spray available in all Mississippi locations GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) is strengthening relationships with partners across sectors and continuing its commitment to ensuring widespread opioid emergency preparedness as opioid overdose death rates continue to decline nationwide for the
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, and Rocketvax Ltd, one of Switzerland's next-generation vaccine companies and a member of the Swiss Rockets Ltd family of companies, today announced entry into an agreement for Emergent's strategic financial investment into Swiss Rockets Ltd, the parent company of Rocketvax Ltd, to support research, infrastructure development, and the expansion of Swiss Rockets' innovative biotechnology portfolio. This endeavor underscores Emergent's commitment to supporting Swi
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lines. As part of the agreement, Emergent will retain the rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collabo
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease in Net Loss of 37% versus prior yearFourth Quarter 2024 Adjusted EBITDA of $21.0 million, increase of 518% versus prior yearFull Year 2024 Adjusted EBITDA of $183.1 million, compares favorably to a loss of $22.3 million in 2023Guiding to 2025 Adjusted EBITDA of $150 - $200 million and improved gross margins GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the quarter and year ended December 31, 2024. "As we close out 2024, I'm proud to share we delivered f
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
GAITHERSBURG, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Monday, March 3, 2025, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2024. Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the cal
Emergent BioSolutions Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target
H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00
Rodman & Renshaw initiated coverage on Emergent BioSolutions with a new price target
Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00
Emergent BioSolutions upgraded by The Benchmark Company with a new price target
The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00
JP Morgan resumed coverage on Emergent BioSolutions
JP Morgan resumed coverage of Emergent BioSolutions with a rating of Underweight
Emergent BioSolutions downgraded by The Benchmark Company
The Benchmark Company downgraded Emergent BioSolutions from Buy to Hold
Emergent BioSolutions upgraded by The Benchmark Company with a new price target
The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $22.00
Emergent BioSolutions downgraded by JP Morgan with a new price target
JP Morgan downgraded Emergent BioSolutions from Neutral to Underweight and set a new price target of $9.00 from $23.00 previously
Emergent BioSolutions downgraded by The Benchmark Company
The Benchmark Company downgraded Emergent BioSolutions from Buy to Hold
Emergent BioSolutions downgraded by Cantor Fitzgerald
Cantor Fitzgerald downgraded Emergent BioSolutions from Overweight to Neutral
Wells Fargo reiterated coverage on Emergent BioSolutions with a new price target
Wells Fargo reiterated coverage of Emergent BioSolutions with a rating of Equal-Weight and set a new price target of $40.00 from $37.00 previously
Emergent BioSolutions Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SVP, Bioservices Hartzel William covered exercise/tax liability with 561 shares, decreasing direct ownership by 0.51% to 109,122 units (SEC Form 4)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
EVP, Quality & Ethics, and CPL Glessner Coleen covered exercise/tax liability with 480 shares, decreasing direct ownership by 0.27% to 176,176 units (SEC Form 4)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
Amendment: SVP, Bioservices Hartzel William was granted 62,500 shares, increasing direct ownership by 132% to 109,683 units (SEC Form 4)
4/A - Emergent BioSolutions Inc. (0001367644) (Issuer)
Director Fowler Neal Franklin sold $204,050 worth of shares (35,000 units at $5.83), decreasing direct ownership by 26% to 101,100 units (SEC Form 4)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
Director Zoon Kathryn C sold $57,300 worth of shares (10,000 units at $5.73), decreasing direct ownership by 18% to 44,482 units (SEC Form 4)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
SEC Form 4 filed by President and CEO Papa Joseph C
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
SVP, General Counsel, Corp Sec Perl Jessica was granted 62,500 shares, increasing direct ownership by 1,062% to 68,387 units (SEC Form 4)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
SVP, Products Business Williams Paul Anthony was granted 62,500 shares, increasing direct ownership by 262% to 86,335 units (SEC Form 4)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
EVP, Chief Financial Officer Lindahl Richard S was granted 146,888 shares, increasing direct ownership by 96% to 299,225 units (SEC Form 4)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
SVP, R&D, CMO Lowry Simon C was granted 62,500 shares, increasing direct ownership by 212% to 91,982 units (SEC Form 4)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
Emergent BioSolutions Inc. SEC Filings
Emergent BioSolutions Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
SEC Form EFFECT filed by Emergent BioSolutions Inc.
EFFECT - Emergent BioSolutions Inc. (0001367644) (Filer)
SEC Form 424B3 filed by Emergent BioSolutions Inc.
424B3 - Emergent BioSolutions Inc. (0001367644) (Filer)
SEC Form DEF 14A filed by Emergent BioSolutions Inc.
DEF 14A - Emergent BioSolutions Inc. (0001367644) (Filer)
SEC Form DEFA14A filed by Emergent BioSolutions Inc.
DEFA14A - Emergent BioSolutions Inc. (0001367644) (Filer)
Emergent BioSolutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
SEC Form POS AM filed by Emergent BioSolutions Inc.
POS AM - Emergent BioSolutions Inc. (0001367644) (Filer)
SEC Form POS EX filed by Emergent BioSolutions Inc.
POS EX - Emergent BioSolutions Inc. (0001367644) (Filer)
SEC Form 424B3 filed by Emergent BioSolutions Inc.
424B3 - Emergent BioSolutions Inc. (0001367644) (Filer)
Emergent BioSolutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
Emergent BioSolutions Inc. Leadership Updates
Live Leadership Updates
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
Ongoing support of the ‘White House Challenge to Save Lives from Overdose' through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emerg
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. ("Bora", TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent's Contract Development and Manufacturing Organization (CDMO), has clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. Alongside the facility, approximately 350 curre
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v
Emergent BioSolutions Announces CEO Transition
Robert G. Kramer Sr. to Retire Haywood Miller to Serve as Interim CEO GAITHERSBURG, Md., June 27, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS, "Emergent" or the "Company"))) today announced that Robert G. Kramer Sr. has informed the Board of Directors of his intention to retire from Emergent. Mr. Kramer will step down from his role as President and CEO of Emergent and as a member of the Company's Board, effective immediately. The Board has appointed Haywood Miller as interim CEO while it conducts a search to identify a new permanent CEO, considering both internal and external candidates and with the assistance of a leading executive search firm. Mr. Miller, Managing Director
Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors
GAITHERSBURG, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company's board of directors appointed Sujata Dayal as a Class II director to serve on the board effective July 15, 2022, with an initial term expiring at the 2023 annual meeting of stockholders. Ms. Dayal was also appointed as a member of both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight. "We are pleased to welcome Sujata Dayal to Emergent's Board of Directors," said Zsolt Harsanyi, Ph.D., chairman of the board of Emergent BioSolutions. "Sujata's deep experience in healthcare compliance and strong experti
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors
NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ
Emergent BioSolutions Inc. Financials
Live finance-specific insights
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease in Net Loss of 37% versus prior yearFourth Quarter 2024 Adjusted EBITDA of $21.0 million, increase of 518% versus prior yearFull Year 2024 Adjusted EBITDA of $183.1 million, compares favorably to a loss of $22.3 million in 2023Guiding to 2025 Adjusted EBITDA of $150 - $200 million and improved gross margins GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the quarter and year ended December 31, 2024. "As we close out 2024, I'm proud to share we delivered f
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
GAITHERSBURG, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Monday, March 3, 2025, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2024. Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the cal
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
Third Quarter 2024 Total Revenues of $293.8 million, increase of 9% versus prior yearThird Quarter 2024 Net Income of $114.8 million, increase of 144% versus prior yearThird Quarter 2024 Adjusted EBITDA of $105.3 million, increase of 432% versus prior yearRaises FY 2024 guidance GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the third quarter ended September 30, 2024. "Through disciplined execution and steady, measurable progress, Emergent's financial position is the strongest it has been since 2021 as evidenced by our favorable third-quarter results," said CEO Joe Papa. "We have successfully improved effici
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024. Webcast & Conference Call InformationParticipants can access the conference call live via webcast. To join via telephone, please use the following dial-in details: U.S. / New York: +1-646-968-2525U.S. & Canada (Toll Free): +1-888-596-4144Conference ID: 5259189 A replay of the call can be accessed from the Investors page of Emergent's website. About Emergent BioSolutionsAt Emergent
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance rangeSecond Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) millionUpdates FY 2024 guidance GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the second quarter ended June 30, 2024. "In the first half of the year, we made great progress to stabilize our financial position by strategically divesting assets, resolving several legacy issues, and securing operational cash flow and working capital improvements," said Joe Papa, president and CEO at Emergent. "As a result, we ex
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of 2024, as well as full year guidance. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that
Emergent BioSolutions Reports First Quarter 2024 Financial Results
First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products," said Joe Papa, President and CEO at Emergent. "We also took significant actions to improve our debt position, reduce operating expenses and strengthen our financial flexibility. Emergent's transformation will not happen overnight. The actions we
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficientlyReorganization will align with evolving business goals, strategic priorities and new operational planOverall efforts expected to deliver annual cost savings of approximately $80 million GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities, and restructures its enterprise workforce to improve the performance and profitability of its business. Emergent will continue to focus on its c
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has entered into a "Consent, Waiver and Seventh Amendment" to its existing credit facility. "In light of this amendment, Emergent now has an extended runway to execute on our go-forward business plan to stabilize our financial position," stated Joe Papa, president and CEO of Emergent. "Our bank group continues to work with our management team in a constructive fashion, evidenced by this positive development." On May 1, 2024, Emergent will report its first quarter 2024 financial results via conference call, as well highlight key business updates, Q1 2024 financial review, and FY 2
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registr
Emergent BioSolutions Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G filed by Emergent BioSolutions Inc.
SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)
Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
Amendment: SEC Form SC 13G/A filed by Emergent Biosolutions Inc.
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SEC Form SC 13G/A filed by Emergent Biosolutions Inc. (Amendment)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SEC Form SC 13G/A filed by Emergent Biosolutions Inc. (Amendment)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SEC Form SC 13G filed by Emergent Biosolutions Inc.
SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)
SEC Form SC 13G/A filed by Emergent Biosolutions Inc. (Amendment)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SEC Form SC 13G/A filed by Emergent Biosolutions Inc. (Amendment)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SEC Form SC 13G/A filed by Emergent Biosolutions Inc. (Amendment)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)